Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Review, H2 2016

  • ID: 3832316
  • Report
  • 33 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Alveonix AG
  • Dompe Farmaceutici S.p.A.
  • RaQualia Pharma Inc.
  • MORE
Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Review, H2 2016

Summary

‘Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Review, H2 2016’, provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted pipeline therapeutics.

The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8)
- The report reviews Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Alveonix AG
  • Dompe Farmaceutici S.p.A.
  • RaQualia Pharma Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Overview

Therapeutics Development

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Stage of Development

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Therapy Area

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Indication

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Products Glance

Early Stage Products

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Companies

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Companies Involved in Therapeutics Development

Alveonix AG

Dompe Farmaceutici S.p.A.

Glenmark Pharmaceuticals Ltd.

RaQualia Pharma Inc.

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Drug Profiles

AVX-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFL-23448 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00203078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00434739 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize TRPM8 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM8 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 33List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Alveonix AG, H2 2016

Pipeline by Dompe Farmaceutici S.p.A., H2 2016

Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016

Pipeline by RaQualia Pharma Inc., H2 2016

Dormant Projects, H2 2016 31List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Alveonix AG
  • Dompe Farmaceutici S.p.A.
  • RaQualia Pharma Inc.
  • MORE
Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Transient receptor potential cation channel subfamily M member 8 (TRPM8) is a protein encoded by the TRPM8 gene. It is activated upon depolarization, changes in temperature resulting in graded shifts of its voltage-dependent activation curves. In prostate cancer cells, it shows strong inward rectification and high calcium selectivity in contrast to its behavior in normal cells which is characterized by outward rectification and poor cationic selectivity. It plays a important role in prostate cancer cell migration.

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by Companies in Preclinical and Discovery stages are 6 and 2 respectively.

Our latest report Transient Receptor Potential Cation Channel Subfamily M Member 8 – Pipeline Review, H2 2016, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Alveonix AG
Dompe Farmaceutici S.p.A.
Glenmark Pharmaceuticals Ltd.
RaQualia Pharma Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll